Life sciences enterprises are increasingly focusing on Real-world Evidence / Real-world Data (RWE/RWD) to promote patient centricity, identify the next opportunity, and demonstrate value for their investments. Enterprises are seeking next-generation solutions to address interoperability and data access challenges. This shift compels providers to innovate their offerings and introduce advanced solutions that enhance analytics and insights, enable interoperability, and enhance data security. Following suit, Oracle has launched its Analytics Intelligence for Life Sciences offering, which provides AI-enabled workflows, enhanced data interoperability, and pre-integrated datasets. In this report, we examine Oracle’s current market position, key product announcements, and industry objectives. We also review Oracle’s RWE/RWD technology and cover essential RWE/RWD issues and objectives for life sciences enterprises.  Scope Industry: life sciences Geography: global Segment: RWE/RWD platforms Contents In this report, we examine: Key enterprise RWE/RWD issues and objectives Oracle’s Analytics Intelligence for Life Sciences announcement Memberships Life Sciences Information Technology Sourcing and Vendor Management

The clinical development landscape is rapidly evolving, with hybrid trial approaches and the growing use of RWD/RWE. Clinical trial sponsors are increasingly challenged to manage the vast volume of data generated during multiple, simultaneously running trials. This data explosion, combined with heightened regulatory scrutiny from bodies like the US FDA, is pushing sponsors to take greater ownership in trial oversight, risk management, and patient safety. The challenge is exacerbated when clinical trials are outsourced, as sponsors lose real-time access to trial data, delaying critical decision-making and risk management. The solution lies in an end-to-end unified clinical Data and Analytics (D&A) platform, which provides a single source of truth by consolidating trial data across multiple solutions, ensuring quality and standardization and delivering real-time trial performance analytics. This report addresses the key challenges sponsors face in managing clinical data, the benefits of deploying an end-to-end unified clinical D&A platform, and implementation considerations. It is tailored to assist biopharma and MedTech enterprises, as well as contract research organizations, in streamlining their clinical data management, enhancing trial oversight, and improving decision-making. Scope Industry: life sciences Geography: global Contents In this report, we outline: The business challenges that sponsors face in managing clinical data An end-to-end unified clinical D&A platform’s benefits Key implementation considerations for clinical D&A platforms Membership(s) Clinical Development Technology Life Sciences Information Technology Sourcing and Vendor Management

In the rapidly evolving life sciences landscape, where the pursuit of innovative therapies and life-saving drugs never ceases, science and technology are increasingly playing a vital role. High-performance Computing (HPC) stands at the forefront of this technology revolution, empowering pharmaceutical and medical device enterprises, as well as research and academia, to unravel the complexities of biology, medicine, and multi-omics like never before. HPC is no longer confined to successful pilot phases but is transitioning to wider adoption, addressing essential business needs across industries, including life sciences. The pharmaceutical industry, dealing with vast volumes of complex and heterogenous data, is an ideal sector for harnessing the benefits of HPC – particularly around intricate biological interactions, complex data analysis, and sophisticated simulations. In this viewpoint, we study HPC’s high-potential use cases in life sciences and how pharmaceutical companies can derive success from their HPC initiatives. Scope Industry: life sciences Geography: global Contents In this report, we explore: HPC’s evolution, including the examination of an HPC-enabled system and the catalysts driving its adoption across industries The current supply ecosystem, highlighting prominent pharmaceutical and medical device HPC use cases The drivers and barriers to HPC adoption and important enterprise considerations before transitioning to HPC A step-based adoption roadmap for life sciences enterprises and a peek into HPC’s future in life sciences Membership(s) Life Sciences Information Technology Outsourcing Excellence

In the past, the manufacturing industry’s primary focus was on creating standard procedures and managing workers and machines. However, with the advent of Industry 4.0, technology has become more prevalent in many sectors, offering numerous benefits. Despite this trend, the life sciences industry has been slow in adopting technology to modernize its manufacturing processes. The pandemic, regulatory changes, and the pursuit of efficiency are now driving the adoption of smart manufacturing services in this sector. Life sciences companies are investing in use cases such as digital twins and predictive maintenance to reduce costs, increase productivity, enhance visibility, and improve overall efficiency. They are also exploring high-growth opportunities such as sustainable manufacturing, batch-to-continuous manufacturing, and personalized medicine production. As the industry invests in smart manufacturing, providers are playing a vital role as end-to-end digital transformation partners, collaborating with companies to develop solutions that facilitate their digital transformation journeys. This compendium provides detailed and fact-based snapshots of 16 smart manufacturing services providers featured on Everest Group’s Life Sciences Smart Manufacturing Services PEAK Matrix®. Each profile offers a comprehensive picture of the provider’s service focus, key IP/solutions, domain investments, and case studies. The study will enable buyers to make the right sourcing decisions based on their requirements, while providers while be able to benchmark themselves against their competitors. Scope: Industry: life sciences Geography: global Contents: In this report, we: Analyze the provider landscape for life sciences smart manufacturing services Assess providers on several capability and market success-related dimensions Membership(s) Life Sciences Information Technology Sourcing and Vendor Management

In the past, the manufacturing industry primarily focused on designing standardized manufacturing procedures and managing labor and mechanical systems. However, the advent of Industry 4.0 has led to the widespread adoption of technology across various sectors, unlocking numerous benefits. Nevertheless, the life sciences industry has been slow in embracing technology to modernize its manufacturing setups. The pandemic, regulatory frameworks, and the drive for operational excellence are now propelling the adoption of smart manufacturing services. Life sciences enterprises are striving to unlock benefits such as cost optimization, increased productivity, visibility, and efficiency through investments in vital use cases such as digital twins and predictive maintenance. They are also exploring high-growth opportunities such as sustainable manufacturing, batch-to-continuous manufacturing, and personalized medicine production. As the industry receives investments in smart manufacturing, providers are assuming the role of end-to-end digital transformation partners by collaboratively developing solutions to assist enterprises in their digital journeys. In this report, we assess 16 life sciences smart manufacturing service providers featured on Everest Group’s Life Sciences Smart Manufacturing Services PEAK Matrix® 2023. Each provider profile offers a comprehensive picture of its service focus, key IP/solutions, domain investments, and case studies. The study will enable buyers to make the right sourcing decisions based on their requirements, while providers will be able to benchmark themselves against their competitors. Scope Industry: life sciences Geography: global The assessment is based on Everest Group’s annual RFI process for the calendar year 2023, interactions with leading life sciences service providers, client reference checks, and an ongoing analysis of the IT services market Contents This report features 16 life sciences smart manufacturing service provider profiles and includes: The provider landscape for life sciences smart manufacturing services Providers’ assessment on several capability and market success-related dimensions Membership(s) Life Sciences Information Technology Sourcing and Vendor Management

Amid the global COVID-19 pandemic, the Life Sciences (LS) industry faced unprecedented challenges that prompted the accelerated adoption of IT services across its value chain. To ensure business continuity, LS enterprises swiftly embraced virtual ecosystems facilitated by IT services. They have actively adopted digital transformation, leading to a surge in the utilization of emerging technologies such as cloud migration, virtual engagement models for clinical trials and sales and marketing, AI/ML for drug discovery, digital twins for manufacturing, real-time IoT visibility for supply chain, and cybersecurity for connected medical devices. Moreover, LS enterprises are prioritizing provider rationalization and IT rationalization to optimize costs and address pricing pressures. Although the LS industry has traditionally been slow in adopting IT, enterprises have embarked on their digital transformation journeys by implementing a digital thread to support and foster emerging use cases. These enterprises seek thought leaders and innovation partners capable of guiding them through their transformation endeavors. Consequently, providers are enhancing their capabilities by developing industry-specific tools and accelerators, as well as engaging in LS-specific partnerships and co-innovation initiatives. In this report, we examine the principal enterprise themes and provide an overview of the general LS IT services market outlook for 2023. Scope Industry: LS Geography: global Contents In this report, we examine: Key enterprise themes that dominated the LS market in 2022 The current market for LS IT services and its projected growth LS IT services deals that are up for renewal The market outlook for 2023 and subsequent years Membership(s) Life Sciences Information Technology Sourcing and Vendor Management

The COVID-19 outbreak compelled the life sciences industry to innovate and transform digitally. However, the current global macroeconomic and socio-political uncertainty, coupled with increasing research and development IT expenditure, have created immense pressure on the pharmaceutical industry to expedite the drug discovery and development process while reducing resource consumption. As a result, pharmaceutical companies are prioritizing investments with the potential for quicker return on investment over moonshot investments. Legacy technologies lack the real-time or data integration capabilities that AI and analytics solutions offer, leading to a lack of visibility for pharmaceutical enterprises into the interplay among stakeholders in the life sciences technology landscape. This has caused pharmaceutical companies to partner with product and IT service providers to improve their in-house talent, reduce time-to-insights, replace obsolete models, and understand fast-evolving customer behavior. Although AI offers significant benefits, it presents unique challenges such as the availability and quality of training datasets from multiple sources, a demand-supply mismatch for talent with industry and technology expertise, and infrastructure and complex integration issues. Therefore, pharmaceutical companies need to prioritize use cases based on specific market requirements and business needs. In this report, we discuss how a blueprint for success can enable enterprises to maximize the value of their AI-empowered initiatives and investments. Scope Industry: life sciences Geography: global Contents In this report, we examine: The current state of AI in the pharmaceutical industry Trends driving the adoption of AI across the pharmaceutical value chain Roadblocks and controversies around AI in the pharmaceutical industry Prominent AI use cases across the pharmaceutical value chain Sourcing considerations for AI solutions and suppliers Membership(s) Life Sciences Information Technology Sourcing and Vendor Management

Decentralized Clinical Trials (DCTs) provide pharmaceutical companies with various benefits, including cost savings, improved patient recruitment and retention, flexible operations, and better data quality. While the technology and data to support DCTs existed before the pandemic, only a few pilots were conducted. Today, the need for remote patient- and site-centric trials has led to increased investments in DCTs by pharma enterprises, and the momentum is expected to accelerate, indicating that DCTs are a lasting trend. Additionally, advances in technology, innovative business models, increased wearables support, regulatory bodies’ push to adopt DCTs, and a holistic approach to clinical trials have strengthened the DCT landscape. In this report, we analyze the current state of the DCT market and deep dive into its adoption, market trends, DCT platform providers’ landscape, enterprise view of DCT platform providers, Environment, Social, and Governance (ESG) initiatives, and emerging technology opportunities in the industry. Scope Industry: life sciences Geography: global Contents In this report, we: Study DCT adoption trends and market dynamics Examine the DCT platform provider landscape Provide an enterprise view of DCT providers Analyze ESG initiatives and emerging technology opportunities in the industry Membership(s) Life Sciences Information Technology Sourcing and Vendor Management

The pandemic necessitated and accelerated the rapid adoption of digital services across the Life Sciences (LS) value chain. As a result, there has been a shift in enterprise mindset to become more customer-centric and invest in digital services such as cybersecurity, cloud migration, virtual engagement models for clinical trials and sales and marketing, AI/ML for drug discovery, and digital twins in manufacturing and supply chain operations to realize their business goals. Today, enterprises are looking for thought leaders and innovation partners to help improve their digital transformation journeys. In response, providers are building industry-specific tools and accelerators and engaging in life sciences-specific partnerships and co-innovation initiatives to improve enterprises’ capabilities. Everest Group’s Life Sciences ITS research program analyses provider capabilities and their impact on the life sciences digital services market. This compendium provides detailed and fact-based snapshots of 31 life sciences digital services providers featured on the Life Sciences Digital Services PEAK Matrix® 2022. Each profile offers a comprehensive view of the provider’s service focus, key Intellectual Property (IP) / solutions, domain investments, and case studies. The assessment is based on Everest Group’s annual RFI process for calendar year 2022, interactions with leading life sciences service providers, client reference checks, and an ongoing analysis of the digital services market. Scope Industry: life sciences Services: digital services Geography: global Contents In this report, we: Assess providers on their market success and capabilities Review each provider’s case studies and recent developments Membership(s) Life Sciences Information Technology Sourcing and Vendor Management

The pandemic necessitated and accelerated the rapid adoption of digital services across the Life Sciences (LS) value chain. Therefore, there has been a conscious shift in enterprise mindset to focus on delivering products and services in a more customer-centric and agile manner. As such, there is a historic surge in investment in digital services such as cybersecurity, cloud migration, virtual engagement models for clinical trials and sales and marketing, AI/ML for drug discovery, and digital twins in manufacturing and supply chain operations. Enterprises today are looking for thought leaders and innovation partners that can help them on their transformation journeys. Consequently, service providers are ramping up capabilities by building industry-specific tools and accelerators and engaging in life sciences-specific partnerships and co-innovation initiatives. Everest Group’s Life Sciences ITS research program analyses service provider capabilities and their impact on the life sciences digital services market. In this research, we present an assessment and detailed profiles of 31 life sciences digital services providers featured on the life sciences digital services PEAK Matrix®. Each provider profile provides a comprehensive picture of its service focus, key Intellectual Property (IP) / solutions, domain investments, and case studies. The assessment is based on Everest Group’s annual RFI process for calendar year 2022, interactions with leading life sciences service providers, client reference checks, and an ongoing analysis of the digital services market. Scope Industry: life sciences Services: digital services Geography: global Contents This report examines: The landscape of service providers for life sciences digital services Assessment of service providers on several capability- and market success-related dimensions Membership(s) Life Sciences Information Technology Sourcing and Vendor Management